For the Inventor, By the Inventor

Enter assignee name

Monheim, Germany

Ucb Pharma Gmbh

USPTO Granted Patents = 64

CIPO Patents = 6

EPO Patents = 31

Trademarks = 7

Forward Citations = 203

Loading Chart...

Loading Chart...

88 inventors (with patents filed for the assignee):

Hans-Michael Wolff (14 out of 28 patents)

Claus Meese (9 out of 18 patents)

Christoph Arth (7 out of 12 patents)

4. Cécile Pegurier (6 out of 6 patents)

5. Thomas Stöhr (6 out of 7 patents)

6. Dieter Scheller (6 out of 6 patents)

7. Christa E Mueller (5 out of 5 patents)

8. Ali El-Tayeb (5 out of 6 patents)

9. Marie Ledecq (5 out of 5 patents)

10. Joerg Hockemeyer (5 out of 5 patents)

11. Thomas Stoehr (5 out of 7 patents)

12. Armin Breitenbach (5 out of 7 patents)

13. Luc Quere (5 out of 11 patents)

14. Laurent Provins (4 out of 15 patents)

15. Alain Merschaert (4 out of 4 patents)

Core Competencies:

GPR17 Modulators

CNS Disorders

Lacosamide

Anticonvulsant Therapy

Rotigotine

Transdermal Delivery Systems

Pharmaceutical Compositions

Chiral Intermediates

Atypical Facial Pain

Parkinson's Disease

Cortical Spreading Depression

Nitrogen Substituted Aminotetralins

64 patents: Sort by Forward Citations

1. 12358875 - N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis (2025-07-15),

2. 12071404 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2024-08-27),

3. 11976056 - Substituted alkoxypyridinyl indolsulfonamides (2024-05-07),

4. 11939319 - Pyridinyl and pyrazinyl-(asa)indolsulfonamides (2024-03-26),

5. 11820746 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2023-11-21),

6. 11345662 - Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides (2022-05-31),

7. 10350174 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2019-07-16),

8. 10149818 - Daily formulation of lacosamide (2018-12-11),

9. 10130589 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2018-11-20),

10. 9925150 - Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine (2018-03-27),

11. 9630908 - Process for preparing lacosamide (2017-04-25),

12. 9446011 - Anticonvulsant combination therapy (2016-09-20),

13. 9364541 - Pharmaceutical compositions comprising Fesoterodine (2016-06-14),

14. 9309215 - Chiral intermediate, process for producing the same and its use in the manufacture of tolterodine, fesoterodine, or the active metabolite thereof (2016-04-12),

15. 9308183 - Therapy for hyperexcitability disorders (2016-04-12),

UCB Pharma GmbH is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative solutions in the fields of neurology and immunology. With over 90 years of experience, UCB is committed to improving the lives of patients and creating value for society. Their diverse portfolio includes breakthrough therapies for epilepsy, Parkinson's disease, multiple sclerosis, and more. UCB's mission is to transform the lives of people living with severe diseases through continuous innovation and collaboration with healthcare professionals and partners worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

64 Patents

#3 in Monheim

#894 in Germany

#11,029 in the World

Monheim, Germany

Ucb Pharma Gmbh

Forward Citations = 203

88 inventors:

Hans-Michael Wolff (14 out of 28 patents)

Claus Meese (9 out of 18 patents)

Christoph Arth (7 out of 12 patents)

4. Cécile Pegurier (6 out of 6 patents)

5. Thomas Stöhr (6 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…